Protalix BioTherapeutics price to book ratio PLX

Market value divided by the book value of the company's net assets, since 2012.

Today, Oct 23, 2026: 2.9×
5-year median: 3.2×
Against its 5-year history: 36th; percentile: 0 is its lowest day, 100 its highest
5-year range: 2.4× to 198×
Peer median: 2.6×

Protalix BioTherapeutics' price to book ratio is 2.9× as of Oct 23, 2026.

That is below its 5-year median of 3.2×, close to the middle of its last 5 years.

Over that time it ranged from 2.4× in Aug 2025 to 198× in Feb 2022.

The median for 10 healthcare stocks of a similar size is 2.6×.

Price to book ratio over time

median 3.2×

The dashed line is the 5-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.9×	2.4×	4.7×
2025	2.8×	2.4×	6.1×
2024	4.2×	2.4×	4.2×
2023	3.4×	2.6×	148×
2022	186×	173×	198×
2021	178×	4.2×	196×
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	24.1×	7.3×	30.1×
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	114×	102×	115×
2012	102×	56.9×	110×

Against its peers

Companies in Healthcare nearest Protalix BioTherapeutics' size, closest first, today.

Company	Price to book ratio
PLXProtalix BioTherapeutics	2.9×
PDEXPro DEX	4.2×
NATRNatures Sunshine Products	1.3×
ELMDElectromed	4.1×
UTMDUtah Medical Products	1.9×
INFUInfuSystem	4.7×
VMDViemed Healthcare	2.6×
EMBCEmbecta	n/m
KEQUKewaunee Scientific	1.3×
ICCCImmucell	3.0×
ARVNArvinas	0.8×
Peer median	2.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Protalix BioTherapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.